Healthcare-Focused Fund Camber Capital’s Top Picks: Masimo Corporation (MASI), The Medicines Company (MDCO)

Camber Capital Management boosted its stake in The Medicines Company (NASDAQ:MDCO) by around 90% during the first quarter to 2.5 million shares, valued at $70.05 million. The $2.0 billion biopharmaceutical company has recently announced that the FDA approved its KENGREAL drug for reducing thrombotic events in patients undergoing therapy to percutaneous coronary intervention (PCI). The development of the drug faced many setbacks and took almost a decade to be approved. Among the largest shareholders of The Medicines Company (NASDAQ:MDCO) are Zach Schreiber’s Point State Capital, Chuck Royce’s Royce & Associates, and Corvex Capital managed by Keith Meister.

Finally, on the fourth spot in the Camber Capital Management’s equity portfolio is Genomic Health, Inc. (NASDAQ:GHDX) in which the fund revealed a $64.16 million position, with 2.1 million shares, down by 50,000 shares compared the prior quarter. Genomic Health is a company that is committed to research and develop the quality of cancer treatment. Its stock is down by 11% year-to-date amid weak financial results with revenue of $68 million, versus $67 million a year earlier and net loss per share expanded to $0.30 from $0.24. The largest shareholders of Genomic Health, Inc. (NASDAQ:GHDX) among the funds from our database are Julian Baker and Felix Baker’s Baker Bros. Advisors with 13.66 million shares and Conan Laughlin’s North Tide Capital with 1.5 million shares.

Disclosure: none